• LifeStance raised full-year 2026 revenue guidance to $1.685-$1.725 billion, a $45 million midpoint increase, implying 20% growth.
• Center Margin outlook lifted to $570-$594 million; Adjusted EBITDA forecast lifted to $215-$235 million, implying a 13.2% margin.
• Updated annual view assumes higher visit volumes, supported by mid-single-digit gains in total revenue per visit.
• Third-quarter guidance: revenue $420-$440 million; Center Margin $140-$152 million; Adjusted EBITDA $49-$59 million.
• Second-quarter results topped expectations: revenue $435 million, visits 2,600,000, total revenue per visit $167, Adjusted EBITDA $66 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LifeStance Health Group Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.